Author

Ben Rothwell

Observed names: B Rothwell, B. Rothwell

Institution: Eli Lilly (United Kingdom)

Observed institutions: RTI International, Eli Lilly (United Kingdom), RTI Health Solutions

ORCID: 0000-0002-0499-6904

Observed ORCID: 0000-0002-0499-6904

OpenAlex ID: A5069317406

Economic Modeling Considerations for Rare Diseases

2018 · Isobel Pearson, Ben Rothwell, et al. · Value in Health · 63

Cost-effectiveness of cardiovascular imaging for stable coronary heart disease

2020 · Simon Walker, Edward Cox, et al. · Heart · 29

Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England

2020 · Ben Rothwell, Christopher Kiff, et al. · PharmacoEconomics - Open · 24

MSR217 Using Propensity Weighting Methods With Real-World Data and Noncontrolled Extension Data From a Clinical Trial to Estimate Long-Term Treatment Effect: An Example in Alzheimer’s Disease

2025 · Marie-Ange Paget, Can Mert, et al. · Value in Health

EE186 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurrence: A United States (US) Payer Perspective

2022 · B Rothwell, K Sheikh, et al. · Value in Health

P78.01 Nivolumab in Second Line Non-Small Cell Lung Cancer – Comparing Real-World Outcomes in England to CheckMate (CM) 017 and 057

2021 · S. Popat, N. Tanna, et al. · Journal of Thoracic Oncology

PCN128 Utility Weight Considerations in Nice Immune Checkpoint Inhibitor Oncology Appraisals

2020 · K. Noon, J. Costello, et al. · Value in Health

Prm187 - a Systematic Review of Utility Estimates in Melanoma in the Adjuvant Setting

2018 · C Masaquel, B Rothwell, et al. · Value in Health

Works count: 8

Citation count: 116

H-index: 3

I10-index: 3